3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags - Cogent Biosciences ( NASDAQ:COGT ) , Opendoor Technologies ( NASDAQ:OPEN )
According to the technical analysis of over 4,400 publicly traded U.S. companies with a market cap exceeding $100 million, three firms signal a potential trend reversal amid overbought conditions. What Happened: QuantumScape Corp. QS, Cogent Biosciences Inc. COGT, and Opendoor Technologies Inc.
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc.
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public ...
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its ...
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 ...
Why Is Cogent Biosciences Stock Soaring On Tuesday? - Cogent Biosciences ( NASDAQ:COGT )
SUMMIT trial met its primary endpoint with an 8.91-point placebo-adjusted TSS improvement at 24 weeks. Cogent aims to file its first NDA for bezuclastinib in non-advanced SM by end of 2025. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest ...
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.
Dow Dips 1%; Mustang Bio Shares Spike Higher - Apogee Therapeutics ( NASDAQ:APGE ) , Artelo Biosciences ( NASDAQ:ARTL )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Monday. The Dow traded down 1% to 44,379.69 while the NASDAQ declined 0.85% to 20,426.99. The S&P 500 also fell, dropping, 0.39% to 6,255.16. Industrials shares jumped by 0.1% on Monday.
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday - Amber International ( NASDAQ:AMBR ) , Baidu ( NASDAQ:BIDU )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of KalVista Pharmaceuticals, Inc. KALV rose sharply during Monday's session after the company announced it won FDA approval for EKTERLY. The U.S.
Why Is Cogent Biosciences Stock Trading Higher On Monday? - Cogent Biosciences ( NASDAQ:COGT )
Bezuclastinib cut total symptom scores by 8.91 points more than placebo at 24 weeks in the SUMMIT trial. 87.4% of treated patients saw ≥50% drop in serum tryptase levels, versus 0% in the placebo group. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis - Cogent Biosciences ( NASDAQ:COGT )
-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks ( -24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference.
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks ( -24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference. p=0.0002 ) , compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute ...
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing - Cogent Biosciences ( NASDAQ:COGT )
Facility provides additional funding for next steps of the Company's growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year, beginning with SUMMIT results in July
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday - AeroVironment ( NASDAQ:AVAV ) , Applied Digital ( NASDAQ:APLD )
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Friday. Shares of Quanex Building Products Corporation NX rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results.
Wall Street Analysts Believe Cogent Biosciences ( COGT ) Could Rally 224.37%: Here's is How to Trade
The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc.
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four pipeline programs during poster ...
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research ( AACR ) Annual Meeting
Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics ...
Is Cogent Biosciences ( COGT ) Stock a Solid Choice Right Now?
Cogent Biosciences (COGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Cogent Biosciences ( NASDAQ:COGT )
65% mean improvement in Total Symptom Score ( TSS ) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- ...
Is Cogent Biosciences ( COGT ) Outperforming Other Medical Stocks This Year?
Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis ( NonAdvSM ) at the 2025 AAAAI Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy ...
Cogent Biosciences to Participate in the Guggenheim Biotech Conference - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim SMID Cap Biotech ... ET.
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will ...
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - NeuroPace ( NASDAQ:NPCE ) , Cogent Biosciences ( NASDAQ:COGT )
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Acelyrin, Inc. SLRN fell sharply in today's pre-market trading. ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.
Why Is Cogent Biosciences Stock Trading Higher On Monday? - Cogent Biosciences ( NASDAQ:COGT )
On Sunday, Cogent Biosciences, Inc. COGT revealed updated clinical results from the Open Label Extension ( OLE ) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis. Non-advanced systemic mastocytosis is a rare disease that involves mast cell ...
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
56% mean improvement in Total Symptom Score ( TSS ) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS ...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis ( AdvSM )
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID ...
Cogent ( COGT ) Up on SUMMIT Study Update Post Positive FDA Meeting
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis ( NonAdvSM ) - Cogent Biosciences ( NASDAQ:COGT )
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains and objective reduction in skin lesions corresponding with symptomatic improvement
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis ( NonAdvSM )
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions ...
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer.
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors ( GIST ) at ASCO Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated lead-in data from the company's ongoing Phase 3 ...
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Marinus Pharma ( NASDAQ:MRNS )
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Shares of Marinus Pharmaceuticals, Inc. MRNS fell sharply in today's pre-market trading after the company issued an update on the Phase 3 RAISE Trial and reported preliminary first quarter 2024 ...
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally. RP2D selected at 100 mg once-daily optimized formulation based on: ...
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis ( NonAdvSM ) at the 2024 AAAAI Annual Meeting
Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET ...
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2024 milestones ahead of its presentation at ...
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the ...
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. ( Nasdaq: COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will ...
Nasdaq Edges Higher; Macy's Shares Jump - Cigna Group ( NYSE:CI ) , Cogent Biosciences ( NASDAQ:COGT )
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Industrials shares rose by 0.8% on Monday.
Dow Surges 100 Points; Cogent Biosciences Shares Plunge - Cigna Group ( NYSE:CI ) , Cogent Biosciences ( NASDAQ:COGT )
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.28% to 36,349.22 while the NASDAQ fell 0.36% to 14,352.34. The S&P 500 also rose, gaining, 0.06% to 4,607.02. Industrials shares rose by 0.9% on Monday.
Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment - Cogent Biosciences ( NASDAQ:COGT )
Cogent Biosciences Inc COGT shared data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis ( AdvSM ) at the American Society of Hematology Annual Meeting & Exposition.
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday - Apellis Pharmaceuticals ( NASDAQ:APLS )
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. Here are some other big stocks recording losses in today's session. Cogent Biosciences, Inc.
US Stocks Mixed; Cigna Shares Spike Higher
US Stocks Mixed. Cigna Shares Spike Higher ...
US Stocks Mixed; Cigna Shares Spike Higher - Cigna Group ( NYSE:CI ) , Cogent Biosciences ( NASDAQ:COGT )
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 20 points on Monday. Following the market opening Monday, the Dow traded up 0.07% to 36,272.54 while the NASDAQ fell 0.26% to 14,366.24. The S&P 500 also fell, dropping, 0.02% to 4,603.60.
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis ( AdvSM )
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose ...
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis ( NonAdvSM )
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week ...
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology ( ASH ) Annual Meeting - Cogent Biosciences ( NASDAQ:COGT )
- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis ( NonAdvSM ) - Additional clinical data update from APEX Part 1 in patients with Advanced Systemic Mastocytosis ( AdvSM ) also to be reviewed
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium - Cogent Biosciences ( NASDAQ:COGT )
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 ( GLOBE NEWSWIRE ) -- Cogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster presentations at the upcoming 2023 San Antonio Breast Cancer ...
